Novartis Pauses Rap-cel Autoimmune Studies After Three Deaths

Company: Novartis · Asset: Rapcabtagene Autoleucel (Rap-cel / YTB323) · Event: Trial Pause After 3 Fatal IEC-HS Events · Scope: 8 Immunology/Neuroscience Studies · Date: August 31, 2026 Summary Novartis temporarily paused screening, randomization and treatment across eight immunology and neuroscience studies of rapcabtagene autoleucel…